FDA Clears BEAM-304's First Human Trial in PKU
The FDA issued IND clearance for BEAM-304, authorizing Beam Therapeutics to begin a Phase 1/2 trial of liver base editing in phenylketonuria, with no human data yet and the platform model untested in the clinic.
The FDA cleared Beam Therapeutics to begin the first human trial of BEAM-304. An IND (Investigational New Drug) clearance authorizes a company to start clinical testing in the US; it is not a drug approval. No one has yet confirmed that BEAM-304 works in people.
Phenylketonuria, or PKU: the PAH gene encodes an enzyme that breaks down phenylalanine from dietary protein. When the enzyme does not work, phenylalanine accumulates in the blood and damages the brain. In the US, newborns are screened for PKU, but early diagnosis does not remove the need for a strict diet, medical food, and chronic disease management.
BEAM-304 targets the root cause. Lipid nanoparticles deliver a base editor to the liver, a tool that changes a single nucleotide in DNA without cutting both strands (unlike standard CRISPR). The first group in the Phase 1/2 trial will be patients with the R408W mutation in the PAH gene. Beam then plans to add an editor for a second mutation, keeping the delivery system and manufacturing process shared.
That is the platform model. Each rare mutation normally requires separate trials, separate manufacturing, and separate regulatory filings, even though the number of patients with any given mutation may be very small. Beam proposes a structure where only the editor changes while delivery, manufacturing, and part of the evidence base remain shared. In early June, the FDA outlined conditions under which data from one gene therapy can be reused for a similar product, but only if the developer explicitly justifies why the transfer is appropriate. There is no automatic carryover.
There are no human data on BEAM-304 yet. In mouse experiments, the therapy normalized phenylalanine levels, and the company said it would present updated preclinical results at the FASEB scientific conference in July. Phase 1/2 will evaluate safety and tolerability first, then blood phenylalanine levels, and finally whether patients can genuinely relax their dietary restrictions.
Open the related Eternal Search page
Sources
[1] investors.beamtx.com
[2] t.me
The BEAM-304 IND clearance is the most concrete recent milestone in base editing for rare genetic disease and illustrates a platform model that, if it holds, changes the economics of rare-mutation therapy development. The linked Eternal Search page offers readers a persistent organizational anchor for tracking how this clinical hypothesis develops as human data emerge.